Radiation Oncology Journal

  • 제33권1호
  • /
  • Pages.12-20
  • /
  • 2015
  • /
  • 2234-1900(pISSN)
  • /
  • 2234-3156(eISSN)
대한방사선종양학회 (The Korean Society for Radiation Oncology)
권호 표지
DOI QR코드

DOI QR Code

Treatment outcomes of neoadjuvant concurrent chemoradiotherapy followed by esophagectomy for patients with esophageal cancer

  • Kim, Yong-Hyub (Department of Radiation Oncology, Chonnam National University Medical School) ;
  • Song, Sang-Yun (Department of Thoracic and Cardiovascular Surgery, Chonnam National University Medical School) ;
  • Shim, Hyun-Jeong (Department of Internal Medicine, Chonnam National University Medical School) ;
  • Chung, Woong-Ki (Department of Radiation Oncology, Chonnam National University Medical School) ;
  • Ahn, Sung-Ja (Department of Radiation Oncology, Chonnam National University Medical School) ;
  • Yoon, Mee Sun (Department of Radiation Oncology, Chonnam National University Medical School) ;
  • Jeong, Jae-Uk (Department of Radiation Oncology, Chonnam National University Medical School) ;
  • Song, Ju-Young (Department of Radiation Oncology, Chonnam National University Medical School) ;
  • Nam, Taek-Keun (Department of Radiation Oncology, Chonnam National University Medical School)
  • 투고 : 2014.11.14
  • 심사 : 2015.01.21
  • 발행 : 2015.03.31
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Purpose: To evaluate treatment outcomes and determine prognostic factors in patients with esophageal cancer treated with esophagectomy after neoadjuvant chemoradiotherapy (NCRT) Materials and Methods: We retrospectively evaluated 39 patients with esophageal cancer who underwent concurrent chemoradiotherapy followed by esophagectomy between 2002 and 2012. Initial clinical stages of patients were stage IB in 1 patient (2.6%), stage II in 5 patients (12.9%), and stage III in 33 patients (84.6%). Results: The median age of all the patients was 62 years, and the median follow-up period was 17 months. The 3-year overall survival (OS) rate was 33.6% in all the patients. The 3-year locoregional recurrence-free survival (LRFS) rate was 33.7%. In multivariate analysis with covariates of age, the Eastern Cooperative Oncology Group performance status, hypertension, diabetes mellitus, tumor length, clinical response, clinical stage, pathological response, pathological stage, lymphovascular invasion, surgical type, and radiotherapy to surgery interval, only pathological stage was an independent significant prognostic factor affecting both OS and LRFS. The complications in postoperative day 90 were pneumonia in 9 patients, anastomotic site leakage in 3 patients, and anastomotic site stricture in 2 patients. Postoperative 30-day mortality rate was 10.3% (4/39); the cause of death among these 4 patients was respiratory failure in 3 patients and myocardial infarction in one patient. Conclusion: Only pathological stage was an independent prognostic factor for both OS and LRFS in patients with esophageal cancer treated with esophagectomy after NCRT. We could confirm the significant role of NCRT in downstaging the initial tumor bulk and thus resulting in better survival of patients who gained earlier pathological stage after NCRT.

키워드

참고문헌

  1. Jung KW, Won YJ, Kong HJ, Oh CM, Lee DH, Lee JS. Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2011. Cancer Res Treat 2014;46:109-23. https://doi.org/10.4143/crt.2014.46.2.109
  2. Pearson JG. The present status and future potential of radiotherapy in the management of esophageal cancer. Cancer 1977;39(2 Suppl):882-90. https://doi.org/10.1002/1097-0142(197702)39:2+<882::AID-CNCR2820390726>3.0.CO;2-X
  3. Kim DE, Kim UJ, Choi WY, et al. Clinical prognostic factors for locally advanced esophageal squamous carcinoma treated after definitive chemoradiotherapy. Cancer Res Treat 2013;45:276-84. https://doi.org/10.4143/crt.2013.45.4.276
  4. Nam TK, Nah BS, Chung WK, Ahn SJ, Song JY. Results of concurrent chemoradiotherapy and intraluminal brachytherapy in esophageal carcinoma: retrospective analysis with respect to survival. J Korean Soc Ther Radiol Oncol 2004;22:25-32.
  5. Shim HJ, Kim DE, Hwang JE, et al. A phase II study of concurrent chemoradiotherapy with weekly docetaxel and cisplatin in advanced oesophageal cancer. Cancer Chemother Pharmacol 2012;70:683-90. https://doi.org/10.1007/s00280-012-1962-3
  6. Yoon MS, Nam TK, Lee JS, et al. VEGF as a predictor for response to definitive chemoradiotherapy and COX-2 as a prognosticator for survival in esophageal squamous cell carcinoma. J Korean Med Sci 2011;26:513-20. https://doi.org/10.3346/jkms.2011.26.4.513
  7. Cooper JS, Guo MD, Herskovic A, et al. Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group. JAMA 1999;281:1623-7.
  8. Herskovic A, Martz K, al-Sarraf M, et al. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med 1992; 326:1593-8. https://doi.org/10.1056/NEJM199206113262403
  9. Minsky BD, Neuberg D, Kelsen DP, Pisansky TM, Ginsberg R, Benson A 3rd. Neoadjuvant chemotherapy plus concurrent chemotherapy and high-dose radiation for squamous cell carcinoma of the esophagus: a preliminary analysis of the phase II intergroup trial 0122. J Clin Oncol 1996;14:149-55. https://doi.org/10.1200/JCO.1996.14.1.149
  10. Minsky BD, Pajak TF, Ginsberg RJ, et al. INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol 2002;20:1167-74. https://doi.org/10.1200/JCO.20.5.1167
  11. Tepper J, Krasna MJ, Niedzwiecki D, et al. Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol 2008;26:1086-92. https://doi.org/10.1200/JCO.2007.12.9593
  12. van Hagen P, Hulshof MC, van Lanschot JJ, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med 2012;366:2074-84. https://doi.org/10.1056/NEJMoa1112088
  13. Oppedijk V, van der Gaast A, van Lanschot JJ, et al. Patterns of recurrence after surgery alone versus preoperative chemoradiotherapy and surgery in the CROSS trials. J Clin Oncol 2014;32:385-91. https://doi.org/10.1200/JCO.2013.51.2186
  14. Fiorica F, Di Bona D, Schepis F, et al. Preoperative chemoradiotherapy for oesophageal cancer: a systematic review and metaanalysis. Gut 2004;53:925-30. https://doi.org/10.1136/gut.2003.025080
  15. Sjoquist KM, Burmeister BH, Smithers BM, et al. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol 2011;12:681-92. https://doi.org/10.1016/S1470-2045(11)70142-5
  16. Urschel JD, Vasan H. A meta-analysis of randomized controlled trials that compared neoadjuvant chemoradiation and surgery to surgery alone for resectable esophageal cancer. Am J Surg 2003;185:538-43. https://doi.org/10.1016/S0002-9610(03)00066-7
  17. Bedenne L, Michel P, Bouche O, et al. Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102. J Clin Oncol 2007;25: 1160-8. https://doi.org/10.1200/JCO.2005.04.7118
  18. Stahl M, Stuschke M, Lehmann N, Meyer HJ, Walz MK, Seeber S, Klump B, Budach W, Teichmann R, Schmitt M, Schmitt G, Franke C, Wilke H. Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol 2005;23:2310-7. https://doi.org/10.1200/JCO.2005.00.034
  19. Borghesi S, Hawkins MA, Tait D. Oesophagectomy after definitive chemoradiation in patients with locally advanced oesophageal cancer. Clin Oncol (R Coll Radiol) 2008;20:221-6. https://doi.org/10.1016/j.clon.2007.12.001
  20. Morita M, Kumashiro R, Hisamatsu Y, et al. Clinical significance of salvage esophagectomy for remnant or recurrent cancer following definitive chemoradiotherapy. J Gastroenterol 2011; 46:1284-91. https://doi.org/10.1007/s00535-011-0448-0
  21. Swisher SG, Wynn P, Putnam JB, et al. Salvage esophagectomy for recurrent tumors after definitive chemotherapy and radiotherapy. J Thorac Cardiovasc Surg 2002;123:175-83. https://doi.org/10.1067/mtc.2002.119070
  22. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228-47. https://doi.org/10.1016/j.ejca.2008.10.026
  23. Berger AC, Farma J, Scott WJ, et al. Complete response to neoadjuvant chemoradiotherapy in esophageal carcinoma is associated with significantly improved survival. J Clin Oncol 2005;23:4330-7. https://doi.org/10.1200/JCO.2005.05.017
  24. Kim MK, Kim SB, Ahn JH, et al. Treatment outcome and recursive partitioning analysis-based prognostic factors in patients with esophageal squamous cell carcinoma receiving preoperative chemoradiotherapy. Int J Radiat Oncol Biol Phys 2008;71:725-34. https://doi.org/10.1016/j.ijrobp.2007.10.009
  25. Schneider PM, Baldus SE, Metzger R, et al. Histomorphologic tumor regression and lymph node metastases determine prognosis following neoadjuvant radiochemotherapy for esophageal cancer: implications for response classification. Ann Surg 2005;242:684-92. https://doi.org/10.1097/01.sla.0000186170.38348.7b
  26. Courrech Staal EF, Aleman BM, Boot H, van Velthuysen ML, van Tinteren H, van Sandick JW. Systematic review of the benefits and risks of neoadjuvant chemoradiation for oesophageal cancer. Br J Surg 2010;97:1482-96. https://doi.org/10.1002/bjs.7175
  27. Scheer RV, Fakiris AJ, Johnstone PA. Quantifying the benefit of a pathologic complete response after neoadjuvant chemoradiotherapy in the treatment of esophageal cancer. Int J Radiat Oncol Biol Phys 2011;80:996-1001. https://doi.org/10.1016/j.ijrobp.2010.03.003
  28. Rohatgi PR, Swisher SG, Correa AM, et al. Failure patterns correlate with the proportion of residual carcinoma after preoperative chemoradiotherapy for carcinoma of the esophagus. Cancer 2005;104:1349-55. https://doi.org/10.1002/cncr.21346
  29. Stiekema J, Vermeulen D, Vegt E, et al. Detecting interval metastases and response assessment using 18F-FDG PET/CT after neoadjuvant chemoradiotherapy for esophageal cancer. Clin Nucl Med 2014;39:862-7. https://doi.org/10.1097/RLU.0000000000000517
  30. Swisher SG, Maish M, Erasmus JJ, et al. Utility of PET, CT, and EUS to identify pathologic responders in esophageal cancer. Ann Thorac Surg 2004;78:1152-60. https://doi.org/10.1016/j.athoracsur.2004.04.046
  31. Alfieri R, Pintacuda G, Cagol M, et al. Oesophageal cancer: assessment of tumour response to chemoradiotherapy with tridimensional CT. Radiol Med 2014 Oct 30 [Epub]. http://dx.doi.org/10.1007/s11547-014-0466-0.
  32. Schneider PM, Metzger R, Schaefer H, et al. Response evaluation by endoscopy, rebiopsy, and endoscopic ultrasound does not accurately predict histopathologic regression after neoadjuvant chemoradiation for esophageal cancer. Ann Surg 2008;248:902-8. https://doi.org/10.1097/SLA.0b013e31818f3afb
  33. Steyerberg EW, Neville BA, Koppert LB, et al. Surgical mortality in patients with esophageal cancer: development and validation of a simple risk score. J Clin Oncol 2006;24:4277-84. https://doi.org/10.1200/JCO.2005.05.0658
  34. Kumagai K, Rouvelas I, Tsai JA, et al. Meta-analysis of postoperative morbidity and perioperative mortality in patients receiving neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal and gastro-oesophageal junctional cancers. Br J Surg 2014;101:321-38. https://doi.org/10.1002/bjs.9418
  35. Chiu CH, Chao YK, Chang HK, et al. Interval between neoadjuvant chemoradiotherapy and surgery for esophageal squamous cell carcinoma: does delayed surgery impact outcome? Ann Surg Oncol 2013;20:4245-51. https://doi.org/10.1245/s10434-013-3139-7

피인용 문헌

  1. Evaluation of Survival Rate and Non-Fetal Outcomes in Patients with Esophageal Cancer Under Treatment with Neoadjuvant Chemoradiotherapy Plus Additional Platinium-Based Chemotherapy from 2010 to 2016 vol.12, pp.6, 2015, https://doi.org/10.5812/ijcm.89003
  2. Influence of different kinds of surgical resection on operation-related clinical indexes, inflammatory cytokines and complications in elderly patients with esophageal cancer vol.36, pp.3, 2015, https://doi.org/10.12669/pjms.36.3.1465
  3. Diabetes mellitus and survival of esophageal cancer patients after esophagectomy: a systematic review and meta-analysis vol.33, pp.2, 2015, https://doi.org/10.1093/dote/doz098